Molecular Diversity ( IF 3.9 ) Pub Date : 2021-09-22 , DOI: 10.1007/s11030-021-10253-z Reema Abu Khalaf 1 , Maha Awad 1 , Luay Al-Essa 1 , Sara Mefleh 1 , Dima Sabbah 1 , Eveen Al-Shalabi 1 , Ihsan Shabeeb 1
|
Abstract
Diabetes mellitus is a main global health apprehension. Macrovascular illnesses, neuropathy, retinopathy, and nephropathy are considered some of its severe hitches. Gliptins are a group of hypoglycemic agents that inhibit dipeptidyl peptidase-IV (DPP-IV) enzyme and support blood glucose-lowering effect of incretins. In the current research, synthesis, characterization, docking, and biological evaluation of fourteen Schiff’s bases 5a–f and 9a–h were carried out. Compound 9f revealed the best in vitro anti-DPP-IV activity of 35.7% inhibition at a concentration of 100 μM. Compounds 9c and 9f with the highest in vitro DPP-IV inhibition were subjected to the in vivo glucose-lowering test using vildagliptin as a positive inhibitor. Vildagliptin, 9c, and 9f showed significant reduction in the blood glucose levels of the treated mice after 30 min of glucose administration. Moreover, induced fit docking showed that these derivatives accommodated the enzyme binding site with comparable docking scores. Schiff’s bases can serve as promising lead for the development of new DPP-IV inhibitors.
Graphical Abstract
中文翻译：
希夫碱作为有前景的二肽基肽酶-IV 抑制剂的发现、合成和组合研究
摘要
糖尿病是全球主要的健康担忧。大血管疾病、神经病、视网膜病和肾病被认为是其严重的障碍。Gliptins 是一组降血糖药，可抑制二肽基肽酶-IV (DPP-IV) 酶并支持肠促胰岛素的降血糖作用。在目前的研究中，对 14 个席夫碱基5a-f和9a-h进行了合成、表征、对接和生物学评价。化合物9f在 100 μM 浓度下显示出最佳的体外抗 DPP-IV 活性，抑制 35.7%。化合物9c和9f以维格列汀为阳性抑制剂，对体外 DPP-IV 抑制最高的患者进行体内降糖试验。维格列汀、9c和9f在给予葡萄糖 30 分钟后显示出治疗小鼠的血糖水平显着降低。此外，诱导拟合对接表明，这些衍生物以相当的对接分数适应酶结合位点。希夫碱可作为开发新 DPP-IV 抑制剂的有希望的先导。
京公网安备 11010802027423号